Very true, the market (or other buyers) determines what it "actually" worth. But Deloitte is no joke when it comes to calculating current/future value based on current and long term assets & liabilities, IP, etc, without emotion or considering "forward-looking" statements.

And yet, all of those calculations can be blown out of the water with a single event, such as a positive Covid trial. Or conversely, negative decisions by current key investors.

This company needs to get on the ball with more assertive and intelligent business decisions and better communications. Potential and 8 years of lead time on competitors in epigenetics aren't worth a wooden nickel, if there is never any "actual" fulfillment. This company needs some "actual" positive news in a very bad way.